Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 65

1.

Impact of clinical, cytogenetic, and molecular profiles on long-term survival after transplantation in patients with chronic myelomonocytic leukemia.

Woo J, Choi DR, Storer BE, Yeung C, Halpern AB, Salit RB, Sorror ML, Woolston DW, Monahan T, Scott BL, Deeg HJ.

Haematologica. 2019 Jul 9. pii: haematol.2019.218677. doi: 10.3324/haematol.2019.218677. [Epub ahead of print]

2.

Correlation of Thyroid Transcription Factor-1 Expression with EGFR Mutations in Non-Small-Cell Lung Cancer: A Meta-Analysis.

Kim HS, Kim JH, Han B, Choi DR.

Medicina (Kaunas). 2019 Feb 7;55(2). pii: E41. doi: 10.3390/medicina55020041.

3.

Prognostic Impact of TTF-1 Expression in Non-Squamous Non-Small-Cell Lung Cancer: A Meta-Analysis.

Kim JH, Kim HS, Kim BJ, Han B, Choi DR, Kwon JH.

J Cancer. 2018 Oct 20;9(22):4279-4286. doi: 10.7150/jca.26830. eCollection 2018.

4.

Extract of Rhus verniciflua stokes protects against renal ischemia-reperfusion injury by enhancing Nrf2-mediated induction of antioxidant enzymes.

Choi DR, Jeong JH, Yu KS, Lee NS, Jeong YG, Kim DK, Na CS, Na DS, Hwang WM, Han SY.

Exp Ther Med. 2018 Apr;15(4):3827-3835. doi: 10.3892/etm.2018.5913. Epub 2018 Feb 28.

5.

Efficacy and tolerability of ramucirumab monotherapy or in combination with paclitaxel in gastric cancer patients from the Expanded Access Program Cohort by the Korean Cancer Study Group (KCSG).

Jung M, Ryu MH, Oh DY, Kang M, Zang DY, Hwang IG, Lee KW, Kim KH, Shim BY, Song EK, Sym SJ, Han HS, Park YL, Kim JS, Lee HW, Lee MH, Koo DH, Song HS, Lee N, Yang SH, Choi DR, Hong YS, Lee KE, Maeng CH, Baek JH, Kim S, Kim YH, Rha SY, Cho JY, Kang YK.

Gastric Cancer. 2018 Sep;21(5):819-830. doi: 10.1007/s10120-018-0806-1. Epub 2018 Feb 9.

PMID:
29427038
6.

Phase II study of oxaliplatin, irinotecan and S-1 therapy in patients with advanced gastric cancer: the Korean Cancer Study Group ST14-11.

Kim HS, Ryu MH, Zang DY, Park SR, Han B, Kang WK, Rha SY, Jung M, Kim JS, Kang BW, Lee KH, Rho SY, Kim JH, Kim KC, Cho JW, Choi DR, Lim H, Kang HS, Soh JS, Kim MJ, Seo J, Kang YK.

Gastric Cancer. 2018 Sep;21(5):802-810. doi: 10.1007/s10120-018-0794-1. Epub 2018 Jan 25.

PMID:
29372461
7.

Multicenter Phase II Study of Oxaliplatin, Irinotecan, and S-1 as First-line Treatment for Patients with Recurrent or Metastatic Biliary Tract Cancer.

Yoo C, Han B, Kim HS, Kim KP, Kim D, Jeong JH, Lee JL, Kim TW, Kim JH, Choi DR, Ha HI, Seo J, Chang HM, Ryoo BY, Zang DY.

Cancer Res Treat. 2018 Oct;50(4):1324-1330. doi: 10.4143/crt.2017.526. Epub 2018 Jan 8.

8.

Oxidative stress caused by activation of NADPH oxidase 4 promotes contrast-induced acute kidney injury.

Jeong BY, Lee HY, Park CG, Kang J, Yu SL, Choi DR, Han SY, Park MH, Cho S, Lee SY, Hwang WM, Yun SR, Ryu HM, Oh EJ, Park SH, Kim YL, Yoon SH.

PLoS One. 2018 Jan 12;13(1):e0191034. doi: 10.1371/journal.pone.0191034. eCollection 2018.

9.

Expression and prognostic significance of microRNAs in Korean patients with myelodysplastic syndrome.

Choi Y, Hur EH, Moon JH, Goo BK, Choi DR, Lee JH.

Korean J Intern Med. 2019 Mar;34(2):390-400. doi: 10.3904/kjim.2016.239. Epub 2017 Nov 15.

10.

Multicenter, cross-sectional observational study of the impact of neuropathic pain on quality of life in cancer patients.

Oh SY, Shin SW, Koh SJ, Bae SB, Chang H, Kim JH, Kim HJ, Hong YS, Park KU, Park J, Lee KH, Lee NR, Lee JL, Jang JS, Hong DS, Lee SS, Baek SK, Choi DR, Chung J, Oh SC, Han HS, Yun HJ, Sym SJ, Yoon SY, Choi IS, Shim BY, Kang SY, Kim SR, Kim HJ.

Support Care Cancer. 2017 Dec;25(12):3759-3767. doi: 10.1007/s00520-017-3806-5. Epub 2017 Jul 8.

11.

Establishment and characterization of hypomethylating agent-resistant cell lines, MOLM/AZA-1 and MOLM/DEC-5.

Hur EH, Jung SH, Goo BK, Moon J, Choi Y, Choi DR, Chung YJ, Lee JH.

Oncotarget. 2017 Feb 14;8(7):11748-11762. doi: 10.18632/oncotarget.14342.

12.

Antimicrobial Activity of Zabofloxacin against Clinically Isolated Streptococcus pneumoniae.

Park HS, Oh SH, Kim HS, Choi DR, Kwak JH.

Molecules. 2016 Nov 17;21(11). pii: E1562.

13.

A dose-finding study for oxaliplatin, irinotecan, and S-1 (OIS) in patients with metastatic or recurrent gastrointestinal cancer.

Han B, Jung JY, Kim HS, Cho JW, Kim KC, Lim H, Kang HS, Ha HI, Kim MJ, Kim JH, Choi DR, Jang G, Kim JH, Song H, Zang DY.

Cancer Chemother Pharmacol. 2016 Nov;78(5):949-958. Epub 2016 Sep 15.

PMID:
27628195
14.

Rhus verniciflua Stokes attenuates cholestatic liver cirrhosis-induced interstitial fibrosis via Smad3 down-regulation and Smad7 up-regulation.

Gil MN, Choi DR, Yu KS, Jeong JH, Bak DH, Kim DK, Lee NS, Lee JH, Jeong YG, Na CS, Na DS, Ryu KH, Han SY.

Anat Cell Biol. 2016 Sep;49(3):189-198. Epub 2016 Sep 29.

15.

Fluoroquinolone resistance of Streptococcus pneumoniae isolates causing invasive disease: special focus on zabofloxacin.

Kim T, Park SJ, Chong YP, Park KH, Lee YM, Hong HL, Kim HS, Kim ES, Lee S, Choi DR, Kim SH, Jeong JY, Lee SO, Choi SH, Woo JH, Kim YS.

Diagn Microbiol Infect Dis. 2016 Oct;86(2):181-3. doi: 10.1016/j.diagmicrobio.2016.07.019. Epub 2016 Jul 22.

PMID:
27498611
16.

Autophagy enhancement contributes to the synergistic effect of vitamin D in temozolomide-based glioblastoma chemotherapy.

Bak DH, Kang SH, Choi DR, Gil MN, Yu KS, Jeong JH, Lee NS, Lee JH, Jeong YG, Kim DK, Kim DK, Kim JJ, Han SY.

Exp Ther Med. 2016 Jun;11(6):2153-2162. Epub 2016 Mar 24.

17.

A Muti-center, Randomized Phase II Study of Oxaliplatin and S-1 versus Capecitabine and Oxaliplatin in Patients with Metastatic Colorectal Cancer.

Kim JH, Zang DY, Chung IJ, Cho SH, Park KU, Oh HS, Lee KH, Lee BH, Kim MJ, Park CK, Han B, Kim HS, Choi DR, Song HH, Jung JY.

J Cancer. 2015 Aug 29;6(10):1041-8. doi: 10.7150/jca.12819. eCollection 2015.

18.

Phase II study of docetaxel, oxaliplatin, and S-1 therapy in patients with metastatic gastric cancer.

Kim HS, Ryu MH, Zang DY, Ryoo BY, Yang DH, Cho JW, Lim MS, Kim MJ, Han B, Choi DR, Kim JH, Jung JY, Song H, Park CK, Kang YK.

Gastric Cancer. 2016 Apr;19(2):579-585. doi: 10.1007/s10120-015-0503-2. Epub 2015 May 22.

PMID:
25997815
19.

The Clinical Utility of FDG PET-CT in Evaluation of Bone Marrow Involvement by Lymphoma.

Kim HY, Kim JS, Choi DR, Kim HS, Kwon JH, Jang GD, Kim JH, Jung JY, Song HH, Lee YK, Min SK, Hwang HS, Kim HJ, Zang DY, Kim HJ.

Cancer Res Treat. 2015 Jul;47(3):458-64. doi: 10.4143/crt.2014.091. Epub 2014 Nov 24.

20.

A phase II study of capecitabine and oral leucovorin as a third-line chemotherapy in patients with metastatic colorectal cancer.

Choi DR, Yoon SN, Kim HS, Kim JH, Kim KY, Kim BC, Choi YK, Kim JB, Han B, Song HH, Zang DY.

Cancer Chemother Pharmacol. 2015 Mar;75(3):639-43. doi: 10.1007/s00280-015-2688-9. Epub 2015 Jan 29.

PMID:
25630415
21.

Phase II study of gemcitabine and S-1 combination chemotherapy in patients with metastatic biliary tract cancer.

Kim HS, Kim HY, Zang DY, Oh HS, Jeon JY, Cho JW, Park CK, Kim JH, Kim MJ, Ha HI, Kim JH, Han B, Song H, Kwon JH, Choi DR, Jung JY.

Cancer Chemother Pharmacol. 2015 Apr;75(4):711-8. doi: 10.1007/s00280-015-2687-x. Epub 2015 Jan 29.

PMID:
25630414
22.

Single-lesion measurement per organ for assessing tumor response in advanced gastric cancer.

Kim HS, Kim JW, Kim JH, Choi DR, Han AR, Kim MJ, Kim BC, Zang DY.

Oncology. 2015;88(2):69-75. doi: 10.1159/000367810. Epub 2014 Oct 1.

PMID:
25277674
23.

The positive effects of one-hour intravenous administration of bortezomib on peripheral neuropathy in multiple myeloma patients.

Jung JY, Kim HY, Han B, Choi DR, Zang DY, Kim HJ.

Biomed Res Int. 2014;2014:237698. doi: 10.1155/2014/237698. Epub 2014 Jun 4.

24.

A Phase II Study to Evaluate the Efficacy of Ramosetron, Aprepitant, and Dexamethasone in Preventing Cisplatin-Induced Nausea and Vomiting in Chemotherapy-Naïve Cancer Patients.

Jang G, Song HH, Park KU, Kim HS, Choi DR, Kwon JH, Kim HY, Han B, Kim JH, Jung JY, Kim HJ, Zang DY.

Cancer Res Treat. 2013 Sep;45(3):172-7. doi: 10.4143/crt.2013.45.3.172. Epub 2013 Sep 30.

25.

Phase II trial of gemcitabine and S-1 for patients with advanced pancreatic cancer.

Song H, Han B, Park CK, Kim JH, Jeon JY, Kim IG, Kim HJ, Jung JY, Kim JH, Kwon JH, Jang G, Kim HY, Kim HS, Choi DR, Zang DY.

Cancer Chemother Pharmacol. 2013 Oct;72(4):845-52. doi: 10.1007/s00280-013-2265-z. Epub 2013 Aug 27.

PMID:
23978987
26.

Phase II study of weekly carboplatin and irinotecan as first-line chemotherapy for patients with advanced non-small cell lung cancer.

Kim HS, Kim JH, Kim B, Choi HC, Kwon JH, Choi DR.

Cancer Chemother Pharmacol. 2013 Jun;71(6):1591-7. doi: 10.1007/s00280-013-2159-0. Epub 2013 Apr 9.

PMID:
23568282
27.

Irinotecan, leucovorin and 5-fluorouracil (modified FOLFIRI) as salvage chemotherapy for frail or elderly patients with advanced gastric cancer.

Kim JH, Kim HS, Han AR, Moh IH, Chung DC, Choi DR, Jang HJ, Kim JB, Yang DH, Lee SI, Zang DY.

Oncol Lett. 2012 Oct;4(4):751-754. Epub 2012 Jul 2.

28.

Predictors of high score patient-reported barriers to controlling cancer pain: a preliminary report.

Kwon JH, Oh SY, Chisholm G, Lee JA, Lee JJ, Park KW, Nam SH, Song HH, Lee K, Zang DY, Kim HY, Choi DR, Kim HJ, Kim JH, Jung JY, Jang G, Kim HS, Won JY, Bruera E.

Support Care Cancer. 2013 Apr;21(4):1175-83. doi: 10.1007/s00520-012-1646-x. Epub 2012 Nov 15.

29.

A phase II study of mitomycin-C and S-1 as third-line chemotherapy in patients with advanced colorectal cancer.

Kim JH, Kim HS, Choi DR, Jang G, Kwon JH, Kim HY, Jung JY, Kim HJ, Song HH, Shin YH, Jung SY, Kim BC, Zang DY.

Oncol Lett. 2011 Nov;2(6):1253-1256. Epub 2011 Jul 27.

30.

Erlotinib in first-line therapy for non-small cell lung cancer: a prospective phase II study.

Choi DR, Lee DH, Choi CM, Kim SW, Suh C, Lee JS.

Anticancer Res. 2011 Oct;31(10):3457-62.

PMID:
21965761
31.

Sunitinib as a second-line therapy for advanced GISTs after failure of imatinib: relationship between efficacy and tumor genotype in Korean patients.

Yoon DH, Ryu MH, Ryoo BY, Beck M, Choi DR, Cho Y, Lee JL, Chang HM, Kim TW, Kang YK.

Invest New Drugs. 2012 Apr;30(2):819-27. doi: 10.1007/s10637-010-9593-1. Epub 2010 Nov 23.

PMID:
21104107
32.

Nilotinib in patients with GIST who failed imatinib and sunitinib: importance of prior surgery on drug bioavailability.

Kim KP, Ryu MH, Yoo C, Ryoo BY, Choi DR, Chang HM, Lee JL, Beck MY, Kim TW, Kang YK.

Cancer Chemother Pharmacol. 2011 Aug;68(2):285-91. doi: 10.1007/s00280-010-1479-6. Epub 2010 Oct 19.

PMID:
20957481
33.

Antimicrobial activity of DW286 against Streptococcus pneumoniae.

Park HS, Jung SJ, Choi DR, Kwak JH.

Int J Antimicrob Agents. 2010 Sep;36(3):230-3. doi: 10.1016/j.ijantimicag.2010.04.007.

PMID:
20627463
34.

Ki-67 expression as a prognostic factor in diffuse large B-cell lymphoma patients treated with rituximab plus CHOP.

Yoon DH, Choi DR, Ahn HJ, Kim S, Lee DH, Kim SW, Park BH, Yoon SO, Huh J, Lee SW, Suh C.

Eur J Haematol. 2010 Aug;85(2):149-57. doi: 10.1111/j.1600-0609.2010.01467.x. Epub 2010 May 6.

PMID:
20477862
35.

DNA gyrase and topoisomerase IV are dual targets of zabofloxacin in Streptococcus pneumoniae.

Park HS, Jung SJ, Kwak JH, Choi DR, Choi EC.

Int J Antimicrob Agents. 2010 Jul;36(1):97-8. doi: 10.1016/j.ijantimicag.2010.02.022. Epub 2010 Apr 18. No abstract available.

PMID:
20403681
36.

Feasibility of BU, CY and etoposide (BUCYE), and auto-SCT in patients with newly diagnosed primary CNS lymphoma: a single-center experience.

Yoon DH, Lee DH, Choi DR, Sohn BS, Kim S, Kim SW, Lee JS, Lee SW, Huh J, Suh C.

Bone Marrow Transplant. 2011 Jan;46(1):105-9. doi: 10.1038/bmt.2010.71. Epub 2010 Apr 12.

PMID:
20383213
37.

A phase II study of pemetrexed and carboplatin as a salvage therapy for platinum-pretreated patients with non-small cell lung cancer.

Kim HS, Lee GW, Kim JH, Kim HY, Kwon JH, Song HH, Kim HJ, Jung JY, Jang G, Choi DR, Park SM, Shin TR, Lee HS, Zang DY.

Lung Cancer. 2010 Oct;70(1):71-6. doi: 10.1016/j.lungcan.2009.12.015. Epub 2010 Jan 21.

PMID:
20096475
38.

Phase II study with fractionated schedule of docetaxel and cisplatin in patients with advanced non-small cell lung cancer.

Kwon JH, Kim JH, Lee JA, Shin HC, Kim HJ, Song HH, Jung JY, Kim HY, Choi DR, Kim HS, Park YI, Zang DY.

Cancer Chemother Pharmacol. 2010 Oct;66(5):889-97. doi: 10.1007/s00280-009-1235-y. Epub 2010 Jan 21.

PMID:
20091311
39.
40.

Bilateral subdural hemorrhage as a possible adverse event of gefitinib in a patient with non-small cell lung cancer.

Kim JH, Kim HS, Choi JS, Lee KM, Shin YC, Ahn BM, Choi DR, Kwon JH, Park S, Kim HY, Jung JY, Kim HJ, Song HH, Zang DY.

Lung Cancer. 2009 Apr;64(1):121-3. doi: 10.1016/j.lungcan.2008.10.007. Epub 2008 Nov 20.

PMID:
19022521
41.

In vitro and in vivo activities of DW-224a, a novel fluoroquinolone antibiotic agent.

Kwon AR, Min YH, Ryu JM, Choi DR, Shim MJ, Choi EC.

J Antimicrob Chemother. 2006 Sep;58(3):684-8. Epub 2006 Jul 27.

PMID:
16873394
42.

Verticillium lecanii spore formulation using UV protectant and wetting agent and the biocontrol of cotton aphids.

Lee JY, Kang SW, Yoon CS, Kim JJ, Choi DR, Kim SW.

Biotechnol Lett. 2006 Jul;28(13):1041-5. Epub 2006 Jun 20.

PMID:
16786263
43.

In vitro and in vivo antibacterial activities of DW-224a, a new fluoronaphthyridone.

Park HS, Kim HJ, Seol MJ, Choi DR, Choi EC, Kwak JH.

Antimicrob Agents Chemother. 2006 Jun;50(6):2261-4.

44.

Antipneumococcal activity of DW-224a, a new quinolone, compared to those of eight other agents.

Kosowska-Shick K, Credito K, Pankuch GA, Lin G, Bozdogan B, McGhee P, Dewasse B, Choi DR, Ryu JM, Appelbaum PC.

Antimicrob Agents Chemother. 2006 Jun;50(6):2064-71.

45.

Vapor phase toxicity of plant essential oils to Cadra cautella (Lepidoptera: Pyralidae).

Sim MJ, Choi DR, Ahn YJ.

J Econ Entomol. 2006 Apr;99(2):593-8.

PMID:
16686164
46.

Antimicrobial activity of DW-224a, a new fluoroquinolone, against Streptococcus pneumoniae.

Kim HJ, Seol MJ, Park HS, Choi DR, Seong SK, Shin HK, Kwak JH.

J Antimicrob Chemother. 2006 Jun;57(6):1256-8. Epub 2006 Apr 7. No abstract available.

PMID:
16603643
47.

Responsiveness to interferon alpha in chronic hepatitis B by presumed vertical transmission.

Jang MK, Choi DR, Lee JY, Moon HK, Lee JH, Kim SM, Kim KH, Park JY, Lee JH, Kim HY, Kim DJ, Lee MS, Park CK, Yoo JY.

J Infect. 2005 Nov;51(4):314-7.

PMID:
16291284
48.

Diastereoselective synthesis of polysubstituted pyrrolidinone as a key intermediate for the anticancer agents by palladium(II)-catalyzed carboxylation.

Choi DR, Lee KY, Chung YS, Joo JE, Kim YH, Oh CY, Lee YS, Ham WH.

Arch Pharm Res. 2005 Feb;28(2):151-8.

PMID:
15789742
49.

Synthesis and cytotoxic activity of 1-(1-benzoylindoline-5-sulfonyl)-4-phenylimidazolidinones.

Jung SH, Lee HS, Kim NS, Kim HM, Lee M, Choi DR, Lee JA, Chung YH, Moon EY, Hwang HS, Seong SK, Lee DK.

Arch Pharm Res. 2004 May;27(5):478-84.

PMID:
15202551
50.

Syntheses and biological evaluation of new fluoroquinolone antibacterials containing chiral oxiimino pyrrolidine.

Choi DR, Shin JH, Yang J, Yoon SH, Jung YH.

Bioorg Med Chem Lett. 2004 Mar 8;14(5):1273-7.

PMID:
14980680

Supplemental Content

Support Center